Profile | GDS2987 / GI_34452700-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 4.7 | 17 |
GSM215244 | HMVEC_vehicle_rep2 | 12.8 | 32 |
GSM215253 | HMVEC_vehicle_rep3 | 29.5 | 63 |
GSM215254 | HMVEC_atorvastatin_rep1 | 38.1 | 64 |
GSM215282 | HMVEC_atorvastatin_rep3 | 55.2 | 69 |
GSM215344 | HMVEC_atorvastatin_rep2 | 8.8 | 22 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 20.3 | 37 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 24 | 44 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | 19.4 | 55 |
GSM215295 | HMVEC_SLx2119_rep2 | 5.1 | 11 |
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 18.9 | 29 |
GSM215298 | PASMC_vehicle_rep2 | 6 | 10 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 9.2 | 15 |
GSM215313 | PASMC_atorvastatin_rep3 | 49.2 | 58 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 23.6 | 38 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 30.7 | 51 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 38.3 | 55 |
GSM215329 | PASMC_SLx2119_rep3 | 7 | 14 |
GSM215330 | Fibroblasts_vehicle_rep1 | 5.9 | 15 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | 24.1 | 57 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 24.2 | 53 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 39.3 | 65 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 26.3 | 53 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 20.4 | 54 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 12.6 | 38 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 10 | 28 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 25 | 56 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 2.7 | 8 |
GSM215341 | Fibroblasts_SLx2119_rep3 |